SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?


To: seminole who wrote (1365)2/13/2001 8:13:32 AM
From: David Cathcart  Read Replies (1) | Respond to of 1826
 
MGI PHARMA Signs Letter Of Intent For Exclusive License To Palonosetron, A Phase 3 Antiemetic For Chemotherapy Induced Nausea And Vomiting, From Helsinn Healthcare SA

"Completion of the Phase 3 trials could allow for NDA (New Drug Application) submission in the first half of 2002. When launched, palonosetron will compete in the $1 billion North American CINV market."

biz.yahoo.com

Looks like a real company is developing...